← Back to Search

Transcranial Direct Current Stimulation + Physical Exercise for Chronic Pain

N/A
Recruiting
Led By Guillaume Léonard, pht, PhD.
Research Sponsored by Université de Sherbrooke
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
To have contraindication to TMS
To have orthopedic limitation or contraindication to physical exercise
Timeline
Screening 3 weeks
Treatment Varies
Follow Up before intervention, follow-up 1 week after intervention, follow-up 1 month after intervention
Awards & highlights

Summary

This trial is testing whether adding transcranial direct current stimulation to physical exercises will help reduce chronic pain in elderly individuals with low corticospinal projections.

Who is the study for?
This trial is for elderly individuals with musculoskeletal chronic pain who haven't been very physically active (less than 150 minutes of exercise per week) and can maintain their current medication and lifestyle during the study. It's not suitable for those with uncontrolled heart disease, orthopedic issues preventing exercise, or contraindications to MRI, TMS, or tDCS.
What is being tested?
The trial is testing if adding transcranial direct current stimulation (tDCS) to physical exercises helps reduce chronic pain more effectively in elderly patients with low corticospinal projections compared to exercises alone.
What are the potential side effects?
Potential side effects from tDCS may include mild discomfort at the electrode site on the scalp, itching, tingling sensations during application, headache, fatigue and nausea. Physical exercise might cause muscle soreness or strain.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot undergo TMS due to health reasons.
Select...
I cannot do physical exercises due to orthopedic reasons.
Select...
I have a heart condition that is not well-managed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before intervention, follow-up 1 week after intervention, follow-up 1 month after intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and before intervention, follow-up 1 week after intervention, follow-up 1 month after intervention for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in Pain intensity
Secondary study objectives
Beck anxiety inventory
Beck depression inventory
Brief pain inventory
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Exercise + real tDCSExperimental Treatment2 Interventions
Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week. For the first week, participants will receive 5 daily sessions of anodal tDCS (2 mA, 20 min).
Group II: Exercise + Sham tDCSPlacebo Group1 Intervention
Intervention will last 8 weeks where participants will be trained at a rate of 3 workouts per week. For the first week, participants will receive 5 daily sessions of sham tDCS.

Find a Location

Who is running the clinical trial?

Université de SherbrookeLead Sponsor
302 Previous Clinical Trials
70,231 Total Patients Enrolled
11 Trials studying Chronic Pain
1,116 Patients Enrolled for Chronic Pain
Guillaume Léonard, pht, PhD.Principal InvestigatorUniversité de Sherbrooke

Media Library

Physical exercise Clinical Trial Eligibility Overview. Trial Name: NCT04332939 — N/A
Chronic Pain Clinical Trial 2023: Physical exercise Highlights & Side Effects. Trial Name: NCT04332939 — N/A
Physical exercise 2023 Treatment Timeline for Medical Study. Trial Name: NCT04332939 — N/A
~7 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top